Pathogenesis of myelofibrosis with myeloid metaplasia: Lessons from mouse models of the disease

被引:6
作者
Vannucchi, AM [1 ]
Migliaccio, AR
Paoletti, F
Chagraoui, H
Wendling, F
机构
[1] Univ Florence, Azienda Osped Careggi, Hematol Unit, I-50134 Florence, Italy
[2] Inst Super Sanita, Cell Biol Lab, Rome, Italy
[3] Univ Florence, Dept Exp Pathol Oncol, Florence, Italy
[4] Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France
关键词
D O I
10.1053/j.seminoncol.2005.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary genetic lesion(s), as well as the biological processes responsible for the typical structural changes of the bone marrow microenvironment in idiopathic myelofibrosis, are still poorly understood, although a central role in disease pathogenesis has been attributed to the clonal proliferation and defective maturation of megakaryocytes. Two animal models of the disease have been described, that in the last few years significantly contributed to the elucidation of some of the pathogenetic steps of the human disease; these are represented by mice genetically modified to overexpress thrombopoietin and by knock-down mice with defective GATA-1 expression in megakaryocytes (GATA-1low mice). This review will outline these murine models, both characterized by extensive accumulation of megakaryocytes in hematopoietic tissues, and illustrate how they provided insights into the identification of some of the molecules and mechanisms responsible for the development of fibrosis and osteosclerosis that present major similarities with those observed in patients with idiopathic myelofibrosis. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:365 / 372
页数:8
相关论文
共 73 条
[1]  
Abina MA, 1998, J IMMUNOL, V160, P4481
[2]   Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression [J].
Abina, MA ;
Tulliez, M ;
Lacout, C ;
Debili, N ;
Villeval, JL ;
Pflumio, F ;
Wendling, F ;
Vainchenker, W ;
Haddada, H .
GENE THERAPY, 1998, 5 (04) :497-506
[3]   Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-mpl [J].
Alexander, WS ;
Roberts, AW ;
Nicola, NA ;
Li, RL ;
Metcalf, D .
BLOOD, 1996, 87 (06) :2162-2170
[4]   TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation [J].
Alliston, T ;
Choy, L ;
Ducy, P ;
Karsenty, G ;
Derynck, R .
EMBO JOURNAL, 2001, 20 (09) :2254-2272
[5]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[6]  
BORDER WA, 1994, NEW ENGL J MED, V331, P1286
[7]   Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA [J].
Cannizzo, SJ ;
Frey, BM ;
Raffi, S ;
Moore, MAS ;
Eaton, D ;
Suzuki, M ;
Singh, R ;
Mack, CA ;
Crystal, RG .
NATURE BIOTECHNOLOGY, 1997, 15 (06) :570-573
[8]   Hematopoietic development: a balancing act [J].
Cantor, AB ;
Orkin, SH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (05) :513-519
[9]  
CarverMoore K, 1996, BLOOD, V88, P803
[10]   THE FREQUENCY AND SIGNIFICANCE OF MEGAKARYOCYTIC EMPERIPOLESIS IN MYELOPROLIFERATIVE AND REACTIVE STATES [J].
CASHELL, AW ;
BUSS, DH .
ANNALS OF HEMATOLOGY, 1992, 64 (06) :273-276